Urinary Angiotensinogen and Progression of Chronic Kidney Disease: Results from KNOW-CKD Study

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2022 Sep 23

PMID 36139118

Authors

Sang Heon Suh

Tae Ryom Oh

Hong Sang Choi

Eun Mi Yang

Chang Seong Kim

Eun Hui Bae

Seong Kwon Ma

Kook-Hwan Oh

Ji Yong Jung

Young Youl Hyun

Soo Wan Kim

Affiliations

Soon will be listed here.

Abstract

The prognostic value of urinary angiotensinogen (UAGT) in patients with chronic kidney disease (CKD) has not been completely evaluated, although the association of UAGT with renal outcomes has been suggested in specific subsets of CKD. In the present study, to investigate the association of UAGT with renal outcomes in patients with non-dialysis CKD irrespective of the primary cause, a total of 1688 subjects from the Korean Cohort Study for Outcomes in Patients With Chronic Kidney Disease (KNOW-CKD) were prospectively analyzed. The subjects were divided into the quintile by UAGT to urine creatinine ratio (UAGT/Cr) level. The primary outcomes of interest were composite renal event, which included decline in kidney function and onset of end-stage renal disease during follow-up periods. The median follow-up duration was 6.257 years. Cox regression model analysis unveiled that the risk of composite renal event was significantly higher in the fifth quintile (adjusted hazard ratio 1.528, 95% confidence interval 1.156 to 2.021) compared to that of the first quartile. The association between high UAGT/Cr level and adverse renal outcome remained consistent in sensitivity analyses, including the analysis of the cause-specific hazard model. Subgroup analyses revealed that the association of UAGT level with renal outcomes is modified by certain clinical contexts, such as BMI and albuminuria. In conclusion, high UAGT level is associated with adverse renal outcomes in patients with non-dialysis CKD. Further studies are warranted to elaborate and expand the predictive role of UAGT as a biomarker for renal outcomes in CKD.

References

Bakris G . Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol. 2008; 3 Suppl 1:S3-10. PMC: 3152266. DOI: 10.2215/CJN.03250807. View

Lee M, Kim S, Kim I, Song S, Kim E, Seo J . Changes in Urinary Angiotensinogen Associated with Deterioration of Kidney Function in Patients with Type 2 Diabetes Mellitus. J Korean Med Sci. 2017; 32(5):782-788. PMC: 5383610. DOI: 10.3346/jkms.2017.32.5.782. View

Ishigaki S, Ohashi N, Aoki T, Matsuyama T, Isobe S, Sato T . Baseline Urinary Angiotensinogen Excretion Predicts Deterioration of the Kidney Function in Patients with Chronic Kidney Disease. Intern Med. 2021; 60(14):2201-2206. PMC: 8355400. DOI: 10.2169/internalmedicine.6599-20. View

Levey A, Eckardt K, Tsukamoto Y, Levin A, Coresh J, Rossert J . Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67(6):2089-100. DOI: 10.1111/j.1523-1755.2005.00365.x. View

Reams G, Villarreal D, Wu Z, Bauer J . Urinary angiotensin II: a marker of renal tissue activity?. Nephron. 1994; 67(4):450-8. DOI: 10.1159/000188215. View

Navar L, Imig J, Zou L, Wang C . Intrarenal production of angiotensin II. Semin Nephrol. 1997; 17(5):412-22. View

Mann J, Schmieder R, McQueen M, Dyal L, Schumacher H, Pogue J . Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008; 372(9638):547-53. DOI: 10.1016/S0140-6736(08)61236-2. View

Kim H, Choi H, Kim C, Bae E, Ma S, Sung S . Effect of urinary angiotensinogen and high-salt diet on blood pressure in patients with chronic kidney disease: results from the Korean Cohort Study for Outcome in Patients with Chronic Kidney Disease (KNOW-CKD). Korean J Intern Med. 2020; 36(3):659-667. PMC: 8137406. DOI: 10.3904/kjim.2020.077. View

Kobori H, Ozawa Y, Suzaki Y, Nishiyama A . Enhanced intrarenal angiotensinogen contributes to early renal injury in spontaneously hypertensive rats. J Am Soc Nephrol. 2005; 16(7):2073-80. PMC: 2001292. DOI: 10.1681/ASN.2004080676. View

10.

Oh K, Park S, Park H, Chin H, Chae D, Choi K . KNOW-CKD (KoreaN cohort study for Outcome in patients With Chronic Kidney Disease): design and methods. BMC Nephrol. 2014; 15:80. PMC: 4050398. DOI: 10.1186/1471-2369-15-80. View

11.

Brasier A, Li J . Mechanisms for inducible control of angiotensinogen gene transcription. Hypertension. 1996; 27(3 Pt 2):465-75. DOI: 10.1161/01.hyp.27.3.465. View

12.

Kobori H, Nishiyama A, Abe Y, Navar L . Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet. Hypertension. 2003; 41(3):592-7. PMC: 2572575. DOI: 10.1161/01.HYP.0000056768.03657.B4. View

13.

Danser A, Saris J, Schuijt M, van Kats J . Is there a local renin-angiotensin system in the heart?. Cardiovasc Res. 2000; 44(2):252-65. DOI: 10.1016/s0008-6363(99)00202-3. View

14.

Yamamoto T, Nakagawa T, Suzuki H, Ohashi N, Fukasawa H, Fujigaki Y . Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease. J Am Soc Nephrol. 2007; 18(5):1558-65. DOI: 10.1681/ASN.2006060554. View

15.

Warnock D . Prevention, protection, and the intrarenal renin-angiotensin systems. Semin Nephrol. 2001; 21(6):593-602. DOI: 10.1053/snep.2001.26806. View

16.

Graciano M, Cavaglieri R, Delle H, Dominguez W, Casarini D, Malheiros D . Intrarenal Renin-Angiotensin system is upregulated in experimental model of progressive renal disease induced by chronic inhibition of nitric oxide synthesis. J Am Soc Nephrol. 2004; 15(7):1805-15. DOI: 10.1097/01.asn.0000131528.00773.a9. View

17.

Kobori H, Urushihara M . Augmented intrarenal and urinary angiotensinogen in hypertension and chronic kidney disease. Pflugers Arch. 2012; 465(1):3-12. PMC: 3515740. DOI: 10.1007/s00424-012-1143-6. View

18.

Park H, Kim J, Cho A, Kim D, Lee Y, Ryu H . Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease. J Korean Med Sci. 2020; 35(22):e165. PMC: 7279941. DOI: 10.3346/jkms.2020.35.e165. View

19.

Sawaguchi M, Araki S, Kobori H, Urushihara M, Haneda M, Koya D . Association between urinary angiotensinogen levels and renal and cardiovascular prognoses in patients with type 2 diabetes mellitus. J Diabetes Investig. 2012; 3(3):318-324. PMC: 4014956. DOI: 10.1111/j.2040-1124.2011.00172.x. View

20.

Kim H, Park S, Jhee J, Yun H, Park J, Han S . Urinary angiotensinogen level is associated with potassium homeostasis and clinical outcome in patients with polycystic kidney disease: a prospective cohort study. BMC Nephrol. 2019; 20(1):104. PMC: 6434770. DOI: 10.1186/s12882-019-1292-3. View